In a strategic move to enhance its manufacturing capabilities, Merck has inaugurated a new $1 billion vaccine manufacturing facility in Durham, North Carolina. This facility is part of Merck’s ...

In another development, Merck has opened a $1 billion vaccine manufacturing facility in Durham, North Carolina, to strengthen its U.S. manufacturing capabilities. The facility incorporates ...

In another development, Merck has opened a $1 billion vaccine manufacturing facility in Durham, North Carolina, to strengthen its U.S. manufacturing capabilities. The facility incorporates advanced ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Kneat's SaaS model automates validation processes in pharma and biotech, reducing errors and ensuring compliance. Learn why ...

The platform additionally allows simulation of disease progression and the response to drug therapies, according to Aitia, which has collaborations in place with AbbVie, Merck & Co, Pfizer ...

Diya Abdeljabbar, director of technical operations at Merck’s vaccine manufacturing center in Durham, said the top attribute he’s seeking is the ability to simplify and explain complex topics.

Aaron completed the Clinical Trial Research Associate Core Competencies program at Durham Technical Community College, equipping him with the foundational knowledge and skills for the industry. In ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...